Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+T cells

Biochemical and Biophysical Research Communications

Volumn 386, Issue 2, 2009, Pages 327-332

  Ohnuma, Kei ^a   Uchiyama, Masahiko ^a,b   Hatano, Ryo ^a   Takasawa, Wataru ^a   Endo, Yuko ^a   Dang, Nam H ^c   Morimoto, Chikao ^a  

^a THE UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Institute of Technology ^*  (Japan)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

Anergy; Caveolin 1; Caveolin 1 Ig; CD26; Costimulation

Indexed keywords

ANTIGEN; CAVEOLIN 1; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; HYBRID PROTEIN; IMMUNOGLOBULIN;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CLONAL ANERGY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD26; CAVEOLIN 1; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CLONAL ANERGY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; RECOMBINANT FUSION PROTEINS;

EID: 67649446162     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.06.027     Document Type: Article

References (32)

1. De Meester I., Korom S., Van Damme J., and Scharpe S. CD26, let it cut or cut it down. Immunol. Today 20 (1999) 367-375
2. Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol. Today 15 (1994) 180-184
3. Morimoto C., and Schlossman S.F. The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 161 (1998) 55-70
4. Tanaka T., Kameoka J., Yaron A., Schlossman S.F., and Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Sci. USA 90 (1993) 4586-4590
5. Ohnuma K., Munakata, Ishii T., et al. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J. Immunol. 167 (2001) 6745-6755
6. Morimoto C., Torimoto Y., Levinson G., et al. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J. Immunol. 143 (1989) 3430-3439
7. Fox D.A., Hussey R.E., Fitzgerald K.A., et al. Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J. Immunol. 133 (1984) 1250-1256
8. Dang N.H., Torimoto Y., Deusch K., Schlossman S.F., and Morimoto C. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J. Immunol. 144 (1990) 4092-4100
9. Reinhold D., Kahne T., Tager M., et al. The effect of anti-CD26 antibodies on DNA synthesis and cytokine production (IL-2, IL-10 and IFN-gamma) depends on enzymatic activity of DP IV/CD26. Adv. Exp. Med. Biol. 421 (1997) 149-155
10. Willheim M., Ebner C., Baier K., et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J. Allergy Clin. Immunol. 100 (1997) 348-355
11. Dang N.H., Torimoto Y., Sugita K., et al. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J. Immunol. 145 (1990) 3963-3971
12. Ohnuma K., Yamochi, Uchiyama M., et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc. Natl. Acad. Sci. USA 101 (2004) 14186-14191
13. Ohnuma K., Uchiyama M., Yamochi T., et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J. Biol. Chem. 282 (2007) 10117-10131
14. Rudd C.E., and Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3 (2003) 544-556
15. Adams A.B., Williams M.A., Jones T.R., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J. Clin. Invest. 111 (2003) 1887-1895
16. Ohnuma K., Ishii T., Iwata S., et al. G1/S cell cycle arrest provoked in human T cells by antibody to CD26. Immunology 107 (2002) 325-333
17. Fujimaki W., Takahashi, Ohnuma K., et al. Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood. Clin. Dev. Immunol. 2oo8 (2008) 305859
18. Ohnuma K., Yamochi T., Uchiyama M., et al. CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells. Mol. Cell. Biol. 25 (2005) 7743-7757
19. Ohnuma K., Dang N.H., and Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 29 (2008) 295-301
20. Tan P., Anasetti C., Hansen J.A., et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J. Exp. Med. 177 (1993) 165-173
21. Gimmi C.D., Freeman G.J., Gribben J.G., et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc. Natl. Acad. Sci. USA 88 (1991) 6575-6579
22. Ohnuma K., Inoue H., Uchiyama M., Yamochi T., Hosono O., Dang N.H., and Morimoto C. T-cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod. Rheumatol. 16 (2006) 3-13
23. Sharpe A.H. Mechanisms of costimulation. Immunol. Rev. 229 (2009) 5-11
24. Jenkins M.K., Pardoll D.M., Mizuguchi J., et al. Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc. Natl. Acad. Sci. USA 84 (1987) 5409-5413
25. Yamada A., Salama A.D., and Sayegh M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13 (2002) 559-575
26. Sharpe A.H., and Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2 (2002) 116-126
27. Abrams J.R., Lebwohl M.G., Guzzo C.A., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103 (1999) 1243-1252
28. Pearson T.C., Alexander D.Z., Winn K.J., Linsley P.S., Lowry R.P., and Larsen C.P. Transplantation tolerance induced by CTLA4-Ig. Transplantation 57 (1994) 1701-1706
29. Weinblatt M., Combe B., Covucci A., et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 54 (2006) 2807-2816
30. Genovese M.C., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353 (2005) 1114-1123
31. Kremer J.M., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349 (2003) 1907-1915
32. Ohnuma K., Takahashi N., Yamochi T., et al. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front. Biosci. 13 (2008) 2299-2310